NCT06075953 2026-03-16
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
Clinical Trials
22 trialsNCT06923527 2026-03-16
Circulating Tumor DNA
Yale University
Phase 2 Recruiting
NCT06638307 2026-03-11
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Stemline Therapeutics, Inc.
Phase 1 Recruiting
NCT05386108 2026-02-05
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2 Recruiting
NCT07222215 2026-01-22
CAPELA
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT05826964 2026-01-13
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
Phase 2 Active not recruiting
NCT05563220 2026-01-06
ELEVATE
Stemline Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06691035 2025-12-04
Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Recruiting
NCT07159451 2025-12-01
POP-ELA
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Recruiting
NCT07242352 2025-11-21
ADAPTela
West German Study Group
Phase 3 Not yet recruiting
NCT06062498 2025-10-20
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
Northwestern University
Phase 2 Recruiting
NCT03778931 2025-09-15
EMERALD
Stemline Therapeutics, Inc.
Phase 3 Completed
NCT05512364 2025-08-19
TREAT ctDNA
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Recruiting
NCT05596409 2025-06-05
ELCIN
Stemline Therapeutics, Inc.
Phase 2 Active not recruiting
NCT07005882 2025-06-05
HELP
Azienda Ospedaliero-Universitaria Careggi
Phase 2 Not yet recruiting
NCT05982093 2025-05-22
SOLTI-2104
SOLTI Breast Cancer Research Group
Phase 2 Active not recruiting
NCT05618613 2025-05-09
ELONA
Context Therapeutics Inc.
Phase 1/2 Terminated
NCT06544577 2024-08-09
Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC
SciClone Pharmaceuticals
Recruiting
NCT04791384 2023-07-27
Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer
Criterium, Inc.
Phase 1/2 Unknown
NCT04797728 2022-10-26
ELIPSE
SOLTI Breast Cancer Research Group
Phase EARLY_PHASE1 Completed
NCT02338349 2022-08-18
A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer
Stemline Therapeutics, Inc.
Phase 1 Completed
NCT02650817 2022-08-18
Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer
Stemline Therapeutics, Inc.
Phase 1 Completed